Loxo Oncology Company Profile (NASDAQ:LOXO)

Analyst Ratings

Consensus Ratings for Loxo Oncology (NASDAQ:LOXO) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.00 (18.86% upside)

Analysts' Ratings History for Loxo Oncology (NASDAQ:LOXO)
Show:
DateFirmActionRatingPrice TargetActions
7/13/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016Stifel NicolausReiterated RatingBuy$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Citigroup Inc.Boost Price TargetBuy$24.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015JMP SecuritiesBoost Price Target$26.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2014Leerink SwannInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Loxo Oncology (NASDAQ:LOXO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/12/2014($12.27)($14.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Loxo Oncology (NASDAQ:LOXO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.77)($0.49)($0.63)
Q2 20161($0.61)($0.61)($0.61)
Q3 20161($0.63)($0.63)($0.63)
Q4 20161($0.65)($0.65)($0.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Loxo Oncology (NASDAQ:LOXO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Loxo Oncology (NASDAQ:LOXO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Loxo Oncology (NASDAQ:LOXO)
DateHeadline
07/14/16 07:00 AMLoxo Oncology (LOXO) Looks Good: Stock Adds 6% in Session -
07/13/16 09:45 AMLoxo Oncology Gets Breakthrough Therapy Status From FDA For LOXO-101 -
07/13/16 08:28 AMLoxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 - [at noodls] - STAMFORD, Conn., July 13, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically ...
07/13/16 07:56 AMNew Strong Buy Stocks for July 13th
06/15/16 08:09 AMLoxo Oncology Accepts Invitation to Present LOXO-101 to the FDA’s Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee - [at noodls] - STAMFORD, Conn., June 15, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically ...
06/14/16 05:59 AMLoxo Oncology to Present at the JMP Securities Life Sciences Conference - [at noodls] - STAMFORD, Conn., June 14, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically ...
06/13/16 04:38 PMLOXO ONCOLOGY, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
06/13/16 03:32 PMLOXO ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of -
06/12/16 04:53 PMPharma lobby 'fighting back' on drug prices
06/10/16 05:11 PMPharma group punches back on drug prices as pressure rises
06/02/16 11:57 AMLoxo Oncology, Inc. :LOXO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
02/26/16 12:42 PMBrokerage Analyst Buys: Solar Capital Ltd. (NYSE:SLRA), TESARO, Inc. (NASDAQ:TSRO), Alcobra Ltd. (NASDAQ ... - RiversideGazette.com - Brokerage Analyst Buys: Solar Capital Ltd. (NYSE:SLRA), TESARO, Inc. (NASDAQ:TSRO), Alcobra Ltd. (NASDAQ ...RiversideGazette.comShares of Loxo Oncology, Inc. (NASDAQ:LOXO) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $30.00 price target according to the covering analysts. During ...
02/26/16 12:42 PMLoxo Oncology Incorporated (NASDAQ:LOXO) Shorted Shares Increased 9.68% After Market Selling - Stock Caller - Loxo Oncology Incorporated (NASDAQ:LOXO) Shorted Shares Increased 9.68% After Market SellingStock CallerLoxo Oncology, Inc. is engaged in discovery, development, and commercialization of targeted cancer therapies. The company has a market cap of $376.29 million. LOXO-101 is the Company's lead product and has completed its pre-clinical research.
02/07/16 01:33 PMLoxo Oncology, Inc: Aisling Capital Iii Lp increased Its Holding - fdanewsalert.com - Loxo Oncology, Inc: Aisling Capital Iii Lp increased Its Holdingfdanewsalert.comAisling Capital Iii Lp filed with SEC a SC 13G/A form about Loxo Oncology, Inc. The form can be accessed here: 000095014216002993. As reported by Aisling Capital Iii Lp, the filler increased its stake in the stock by 9.06% for 3,796,362 shares. Aisling ...and more »
01/31/16 12:35 PMCompany Shares of Loxo Oncology, Inc. (NASDAQ:LOXO) Rally 3.51% - Bull Report - Company Shares of Loxo Oncology, Inc. (NASDAQ:LOXO) Rally 3.51%Bull ReportShares of Loxo Oncology, Inc. (NASDAQ:LOXO) appreciated by 3.51% during the past week but lost 27.38% on a 4-week basis. The shares have outperformed the S&P 500 by 1.73% in the past week but underperformed the index by 23.5% in the last 4 ...
01/25/16 12:38 PMLoxo Oncology, Inc. (NASDAQ:LOXO) - Stock Sentiment And ABR Update - Investor Newswire - Loxo Oncology, Inc. (NASDAQ:LOXO) - Stock Sentiment And ABR UpdateInvestor NewswireZacks Research has given an average broker rating of 1 to Loxo Oncology, Inc. (NASDAQ:LOXO)'s shares. Zacks assigns a simplified score in between one and five against the complex analysts' ratings. A score towards 1-2 typically means a consensus Buy, ...and more »
01/15/16 06:12 AMLoxo Oncology Announces EMA Orphan Drug Designation Granted to LOXO-101 for Treatment of Soft Tissue Sarcoma - [at noodls] - Released OnJan 15, 2016 View PDF , (GLOBE NEWSWIRE) -- (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, ...
01/15/16 06:09 AMCoverage initiated on Loxo Oncology by Citigroup -
01/15/16 05:45 AM6:45 am Loxo Oncology: The European Medicines Agency has granted the co orphan drug designation for LOXO-101 for treatment of patients with soft tissue sarcoma -
01/07/16 03:02 PMLOXO ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
12/22/15 06:20 AMLoxo Oncology Announces First Patient Enrolled in Phase 1 Trial of LOXO-101 in Pediatric Cancer Patients - [at noodls] - Released OnDec 22, 2015 View PDF , (GLOBE NEWSWIRE) -- (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, ...
12/08/15 12:17 PMLOXO ONCOLOGY, INC. Financials -
11/17/15 03:59 PMLoxo Oncology Announces the Closing of Its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - [at noodls] - Loxo Oncology Announces the Closing of Its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
11/12/15 03:06 PMLOXO ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statement -
11/11/15 06:16 PMLoxo Oncology Prices Follow-On Offering of Common Stock - [at noodls] - Loxo Oncology Prices Follow-On Offering of Common Stock
11/10/15 03:26 PMLoxo Oncology Announces Proposed Public Offering of Common Stock - [at noodls] - Loxo Oncology Announces Proposed Public Offering of Common Stock
11/10/15 06:16 AMLoxo Oncology to Present at Upcoming Investor Conferences - [at noodls] - Loxo Oncology to Present at Upcoming Investor Conferences
11/10/15 06:16 AMLoxo Oncology Announces Third Quarter 2015 Financial Results and Provides Program Updates - [at noodls] - Loxo Oncology Announces Third Quarter 2015 Financial Results and Provides Program Updates

Social

About Loxo Oncology

Loxo Oncology logoLoxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: LOXO
  • CUSIP:
Key Metrics:
  • Previous Close: $25.24
  • 50 Day Moving Average: $24.46
  • 200 Day Moving Average: $23.08
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $497.43M
  • Beta: 2.48
  • Current Year EPS Consensus Estimate: $-2.40 EPS
  • Next Year EPS Consensus Estimate: $-3.04 EPS
Additional Links:
Loxo Oncology (NASDAQ:LOXO) Chart for Wednesday, July, 27, 2016